Professor Tony Gershlick

Department of Cardiovascular Sciences
University of Leicester,  
Clinical Sciences Wing
Glenfield General Hospital
Leicester, LE3 9QP

Tel: +44 (0)116 250 2677
Email: agershlick@aol.com

Personal details

Honorary Professor of Interventional Cardiology, University of Leicester

Consultant Cardiologist, University Hospitals of Leicester NHS Trust

  • BSc, Pharmacological Biochemistry 1973
  • MB BS 1976
  • MRCP 1980
  • FRCP 1994

Contact: For NHS enquiries, please email Michelle Moore on michelle.moore@uhl-tr.nhs.uk or telephone +44 (0)116 258 3887.

External positions

  • British Cardiovascular Intervention Society (BCIS)
    Council Member 1994-2000
    Seconded member 2000-2004 
    Scientific Advisor 2004-2009
    Scientific Information Officer (BCIS) 2005-
    BCIS R&D Committee 2007-
    BCIS Audit Group 2009-2012
  • British Cardiovascular Society (formerly British Cardiac Society)
    British Cardiac Society Academic Committee 2003-
    Council Member 2004-08
    Programme Committee 2006–2012
  • Department of Health
    Member Steering and the Data Oversight Committee National Infarct  Angioplasty Project  (NIAP)  2003-07  
    NIAP Steering and Data Overview Committee 2006 -2008       
    NIAP Academic Group 2008-
  • National Institute for Clinical Excellence (N.I.C.E)
    Medical Expert ‘Stents’ and ‘Drug Eluting Stents’ 2002-2004, 2006, 2008
    NICE Working party and Scoping Committee 2008
    Medical expert new antiplatelet agents Prasugrel (2009) Tricagrelor (2011)
  • British Heart Foundation
    Project Grants Committee  2006-2010
  • Medical Research Council
    Panel Member DPFS Awards 2010-2014
  • European Heart Journal
    Editorial Board 2008-
  • European Society of Cardiology 
    European representative on the Faculty Guidelines Committee 2005
    AHA/ACC  Guidelines Committee
    European PCI Scientific Committee (proposed 2006-)
    Collaborative founder – European CTO club 2007- 
    Council member EAPCI Scientific group (ESC affiliated) 2009-2010
  • Other National and International Activities 
    Initiator first Live National Course on left Main Stem Angioplasty 2003
    Initiator first Live National Course on Chronic Total Occlusions 2003 
    Presenter of live interventional cases to TCT Washington, 2000, 2003, 2005
    Live case transmission to ACI 2013

Website

 

Publications

Gershlick AH, Banning AP, Myat A, Verheugt FW, Gersh BJ. Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention? Lancet. 2013 Aug 17;382(9892):624-32.

Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013 Apr 11;368(15):1379-87

Kelly DJ, McCann GP, Blackman D, Curzen NP, Dalby M, Greenwood JP, Fairbrother K, Shipley L, Kelion A, Heatherington S, Khan JN, Nazir S, Alahmar A, Flather M, Swanton H, Schofield P, Gunning M, Hall R, Gershlick AH. Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. EuroIntervention. 2013 Feb 22;8(10):1190-8.

Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) Eur Heart J. 2012 Oct;33(20):2569-619.

Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary interventionJACC Cardiovasc Interv. 2011 Feb 4 2 191-7

Carver A, Rafelt S, Gershlick AH, Fairbrother KL, Hughes S, Wilcox R; REACT Investigators. Longer-term follow-up of patients recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial. J Am Coll Cardiol. 2009 Jul 7;54(2):118-26.

Recent papers

Gunarathne A, Alahmar A, Gershlick AH. 2016. Data supporting the use of the radial approach as the default strategy in octogenarians undergoing primary-PCI? Int J Cardiol. 208:60-4.

Bainey KR, Fresco C, Zheng Y, Halvorsen S, Carvalho A, Ostojic M, Goldstein P, Gershlick AH, Westerhout CM, Van de Werf F, Armstrong PW; STREAM Investigators. 2016. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction. Heart. 102(7): 527-33.

Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA, Radaelli F, Knight E, Gralnek IM, Hassan C, Dumonceau JM. 2016. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy. 48(4): 385-402.

Yeh RW, Secemsky EA, Kereiakes DJ, Normand ST, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. 2016. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 315(16):1735-1749.

Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA, Radaelli F, Knight E, Gralnek IM, Hassan C, Dumonceau JM. 2016. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Gut. 65(3): 374-89.

Maznyczka AM, Howard JP, Banning AS, Gershlick AH. 2016. A propensity matched comparison of return to work and quality of life after stenting or coronary artery bypass surgery. Open Heart. 3(1): e000322.

Jolly SS, Cairns JA, Yusuf S, Rokoss MJ, Gao P, Meeks B, Kedev S, Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemela K, Bernat I, Cantor WJ, Cheema AN, Steg PG, Welsh RC, Sheth T, Bertrand OF, Avezum A, Bhindi R, Natarajan MK, Horak D, Leung RC, Kassam S, Rao SV, El-Omar M, Mehta SR, Velianou JL, Pancholy S, Džavík V; TOTAL Investigators. 2016. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet. 387(10014): 127-35.

Banning AS, Gershlick AH. 2016. Complete revascularisation in patients with ST-segment elevation myocardial infarction and multivessel disease: contemporary data in context. Evid Based Med. 21(2): 73-4.

McCann GP, Khan JN, Greenwood JP, Nazir SA, Dalby M, Curzen N, Hetherington S, Kelly DJ, Blackman DJ, Ring A, Peebles C, Wong J, Sasikaran T, Flather M, Swanton H, Gershlick AH. 2016. The randomised Complete versus Lesion-only PRimary percutaneous coronary Intervention Trial: Cardiovascular Magnetic Resonance imaging substudy (CvLPRIT-CMR). Southampton (UK): NIHR Journals. Library. Efficacy and Mechanism Evaluation, No. 3.1

Matteau A, Yeh RW, Camenzind E, Steg PG, Wijns W, Mills J, Gershlick A, de Belder M, Ducrocq G, Mauri L. 2015. Balancing Long-Term Risks of Ischemic and Bleeding Complications after Percutaneous Coronary Intervention with Drug-Eluting Stents. Am J Cardiol. 116(5): 686-93.

Banning AS, Gershlick AH. 2015. Management of Multivessel Coronary Disease in ST-segment Elevation Myocardial Infarction. Curr Cardiol Rep. 17(9): 75.

Riegger J, Byrne RA, Joner M, Chandraratne S, Gershlick AH, Ten Berg JM, Adriaenssens T, Guagliumi G, Godschalk TC, Neumann FJ, Trenk D, Feldman LJ, Steg PG, Desmet W, Alfonso F, Goodall AH, Wojdyla R, Dudek D, Philippi V, Opinaldo S, Titova A, Malik N, Cotton J, Jhagroe DA, Heestermans AA, Sinnaeve P, Vermeersch P, Valina C, Schulz C, Kastrati A, Massberg S; Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators; Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort PRESTIGE Investigators. 2015. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium†. Eur Heart J.

Shavadia J, Zheng Y, Dianati Maleki N, Huber K, Halvorsen S, Goldstein P, Gershlick AH, Wilcox R, Van de Werf F, Armstrong PW. 2015. Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? J Am Heart Assoc. 4(8): pii: e002049.

Maznyczka AM, Gershlick AH. 2015. Therapeutic hypothermia in patients with out-of-hospital arrest. Heart. 101(16): 1265-71.

Grundeken MJ, Lansky A, Tanguay JF, Gershlick A, Baumbach A, Cuisset T. 2015. Will this trial change my practice? The Dual Antiplatelet Therapy (DAPT) study - 12 or 30 months of dual antiplatelet therapy after drug-eluting stents. EuroIntervention. 11(3): 364-5.

Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann GP. 2015. Reply: Complete Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI: Is It Really What We Should Be Doing? J Am Coll Cardiol. 66(3): 332-3.

El-Hayek GE, Gershlick AH, Hong MK, Dominguez AC, Banning A, Afshar AE, Herzog E, Tamis-Holland JE. 2015. Meta-Analysis of Randomized Controlled Trials Comparing Multivessel versus Culprit-Only Revascularization for Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Disease Undergoing Primary Percutaneous Coronary Intervention. Am J Cardiol. 115(11): 1481-6.

Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L; DAPT Study Investigators. 2015. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 65(20): 2211-21.

Gershlick AH, Westerhout CM, Armstrong PW, Huber K, Halvorsen S, Steg PG, Ostojic M, Goldstein P, Carvalho AC, Van de Werf F, Wilcox RG. 2015. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. Heart. 101(9): 692-8.

Khan JN, Singh A, Nazir SA, Kanagala P, Gershlick AH, McCann GP. 2015. Comparison of cardiovascular magnetic resonance feature tracking and tagging for the assessment of left ventricular systolic strain in acute myocardial infarction. Eur J Radiol. 84(5): 840-8.

Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, Kedev S, Thabane L, Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemelä K, Steg PG, Bernat I, Xu Y, Cantor WJ, Overgaard CB, Naber CK, Cheema AN, Welsh RC, Bertrand OF, Avezum A, Bhindi R, Pancholy S, Rao SV, Natarajan MK, ten Berg JM, Shestakovska O, Gao P, Widimsky P, Džavík V; TOTAL Investigators. 2015. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 372(15): 1389-98.

Ludman PF, Moat N, de Belder MA, Blackman DJ, Duncan A, Banya W, MacCarthy PA, Cunningham D, Wendler O, Marlee D, Hildick-Smith D, Young CP, Kovac J, Uren NG, Spyt T, Trivedi U, Howell J, Gray H; on behalf of the UK TAVI Steering Committee and the National Institute for Cardiovascular Outcomes Research, Toff W, Gershlick A. 2015. Transcatheter Aortic Valve Implantation in the UK: Temporal Trends, Predictors of Outcome and 6 Year Follow Up: A Report from the UK TAVI Registry 2007 to 2012. Circulation. 131(13): 1181-90.

Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. 2015. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 313(11): 1113-21.

Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann GP. 2015. Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease: The CvLPRIT Trial. J Am Coll Cardiol. 65(10): 963-72.

Dohi T, Maehara A, Brener SJ, Généreux P, Gershlick AH, Mehran R, Gibson CM, Mintz GS, Stone GW. 2015. Utility of Peak Creatine Kinase-MB Measurements in Predicting Myocardial Infarct Size, Left Ventricular Dysfunction, and Outcome After First Anterior Wall Acute Myocardial Infarction (from the INFUSE-AMI Trial). Am J Cardiol. 115(5): 563-70.

Khan JN, Nazir SA, Horsfield MA, Singh A, Kanagala P, Greenwood JP, Gershlick AH, McCann GP.2015. Comparison of semi-automated methods to quantify infarct size and area at risk by cardiovascular magnetic resonance imaging at 1.5T and 3.0T field strengths. BMC Res Notes. 8: 52.

McCann GP, Khan JN, Greenwood JP, Nazir S, Dalby M, Curzen N, Hetherington S, Kelly DJ, Blackman DJ, Ring A, Peebles C, Wong J, Sasikaran T, Flather M, Swanton H, Gershlick AH. 2015. Complete Versus Lesion-Only Primary PCI: The Randomized Cardiovascular MR CvLPRIT Substudy. J Am Coll Cardiol. 66(24): 2713-24.

Henry TD, Gershlick A. 2015. Going Beyond the Hard Endpoints: "Quality of Life" May Be Dependent on Quality of Available Data. J Am Coll Cardiol. 66(19): 2114-5.

Kelly DJ, Gershlick AH, Greenwood JP, McCann GP. 2015. Reply: Culprit Artery Only or Multivessel Primary PCI: The Debate Continues. J Am Coll Cardiol. 66(15): 1745-6.

Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; DAPT Study Investigators. 2015. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC Cardiovasc Interv. 8(12): 1552-62.

Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, Mehran R, Gershlick AH, Tölg R, Anette Fiedler K, Abdel-Wahab M, Kufner S, Schneider S, Schunkert H, Ibrahim T, Mehilli J, Kastrati A; and for the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Investigators. 2014. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J. 35(34): 2285-2294.

Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki E, Bogaerts K, Van de Werf F; STREAM investigators. 2014. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation. 130(14): 1139-45.

Nazir SA, Khan JN, Mahmoud IZ, Greenwood JP, Blackman DJ, Kunadian V, Been M, Abrams KR, Wilcox R, Adgey AA, McCann GP, Gershlick AH. 2014. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial. Trials. 15(1): 371.

Welsh RC, Van de Werf F, Westerhout CM, Goldstein P, Gershlick AH, Wilcox RG, Danays T, Bluhmki E, Lopes RD, Steg PG, Armstrong PW. 2014. Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study). Am J Cardiol. 114(6): 811-9.

Camenzind E, Boersma E, Wijns W, Mauri L, Rademaker-Havinga T, Ordoubadi FF, Suttorp MJ, Al Kurdi M, Steg PG; PROTECT Steering Committee and Investigators; Incl Gershlick A. 2014. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. Eur Heart J. 35(29): 1932-48.

George S, Cockburn J, Clayton TC, Ludman P, Cotton J, Spratt J, Redwood S, de Belder M, de Belder A, Hill J, Hoye A, Palmer N, Rathore S, Gershlick A, Di Mario C, Hildick-Smith D; British Cardiovascular Intervention Society; National Institute for Cardiovascular Outcomes Research. 2014. Long-term follow-up of elective chronic total coronary occlusion angioplasty: analysis from the U.K. Central Cardiac Audit Database. J Am Coll Cardiol. 64(3): 235-43.

Khan JN, Razvi N, Nazir SA, Singh A, Masca NG, Gershlick AH, Squire I, McCann GP. 2014. Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction. J Cardiovasc Magn Reson. 16(1): 38.

Schulz S, Richardt G, Laugwitz KL, Mehran R, Gershlick AH, Morath T, Mayer K, Neudecker J, Tölg R, Ibrahim T, Hauschke D, Braun D, Schunkert H, Kastrati A, Mehilli J; for the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Investigators. 2014. Comparison of Prasugrel and Bivalirudin vs Clopidogrel and Heparin in Patients With ST-Segment Elevation Myocardial Infarction: Design and Rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Trial. Clin Cardiol. 37(5): 270-276.

Jolly SS, Cairns J, Yusuf S, Meeks B, Shestakovska O, Thabane L, Niemelä K, Steg PG, Bertrand OF, Rao SV, Avezum A, Cantor WJ, Pancholy SB, Moreno R, Gershlick A, Bhindi R, Welsh RC, Cheema AN, Lavi S, Rokoss M, Džavík V. 2014. Design and rationale of the TOTAL trial: A randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. Am Heart J. 167(3): 315-321.e1.

Brener SJ, Dambrink JH, Maehara A, Chowdhary S, Gershlick AH, Genereux P, Koolen J, Mehran R, Fahy M, Gibson CM, Stone GW. 2014. Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI. EuroIntervention. 9(10): 1195-201.

Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators; incl Gershlick A. 2014. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. J Am Coll Cardiol. 371(23): 2155-66.

Kunadian V, Qiu W, Ludman P, Redwood S, Curzen N, Stables R, Gunn J, Gershlick A; National Institute for Cardiovascular Outcomes Research. 2014. Outcomes in patients with cardiogenic shock following percutaneous coronary intervention in the contemporary era: an analysis from the BCIS database (British Cardiovascular Intervention Society). JACC Cardiovasc Interv. 7(12): 1374-85.

Dianati Maleki N, Van de Werf F, Goldstein P, Adgey JA, Lambert Y, Sulimov V, Rosell-Ortiz F, Gershlick AH, Zheng Y, Westerhout CM, Armstrong PW. 2014. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early after Myocardial infarction trial. Heart. 100(19): 1543-1549.

Hamon M, Bonello L, Marso S, Rao SV, Valgimigli M, Verheugt F, Gershlick A, Wang Y, Prats J, Steg GP, Deliargyris E. 2014. Comparison of bivalirudin versus heparin(s) during percutaneous coronary interventions in patients receiving prasugrel: a propensity-matched study. Clin Cardiol. 37(1): 14-20.

Malik N, Gershlick AH. 2013. The clinical and economic impact of bivalirudin for percutaneous coronary intervention. Expert Rev Pharmacoecon Outcomes Res. 13: 699-706.

Gershlick AH, Banning AP, Myat A, Verheugt FW, Gersh BJ. 2013. Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention? Lancet. 382: 624-632.

Armstrong PW, Gershlick AH, Van de Werf F; STREAM Study Group. 2013. Fibrinolysis or primary PCI in myocardial infarction. N Engl J Med. 369: 280-281.

Gunarathne A, Hunt J, Gershlick A. 2013. Aorto-right atrial and right ventricular fistulae: a very rare complication of native bicuspid aortic valve endocarditis. Heart. 99: 1708.

Brener SJ, Dambrink JH, Maehara A, Chowdhary S, Gershlick AH, Genereux P, Koolen J, Mehran R, Fahy M, Gibson CM, Stone GW. 2013. Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI. EuroIntervention. 9(10):1195-201

Di Mario C, Hildick-Smith D, Gershlick A, Ghione M, Agudo P, Alahmar A, Galassi A, Werner GS. 2013. Highlights from The Experts "Live", 4th annual congress of the Euro CTO Club, London 2012. EuroIntervention. 8: 1359-1361.

Wrigley BJ, Dubey G, Spyt T, Gershlick AH. 2013. Hybrid revascularisation in multivessel coronary artery disease: could a combination of CABG and PCI be the best option in selected patients? EuroIntervention. 8: 1335-1341.

Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. 2013. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 368: 1379-1387.

Kelly DJ, McCann GP, Blackman D, Curzen NP, Dalby M, Greenwood JP, Fairbrother K, Shipley L, Kelion A, Heatherington S, Khan JN, Nazir S, Alahmar A, Flather M, Swanton H, Schofield P, Gunning M, Hall R, Gershlick AH. 2013. Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. EuroIntervention. 8: 1190-1198.

Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Boersma E, Vranckx P, McFadden E, Serruys PW, O'Neil WW, Jorissen B, Van Leeuwen F, Steg PG; PROTECT Steering Committee and Investigators. Incl Gershlick AH. 2013. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet. 380: 1396-1405.

Task Force Members, Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, Van't Hof A, Widimsky P, Zahger D; ESC Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Hasdai D, Astin F, Aström-Olsson K, Budaj A, Clemmensen P, Collet JP, Fox KA, Fuat A, Gustiene O, Hamm CW, Kala P, Lancellotti P, Maggioni AP, Merkely B, Neumann FJ, Piepoli MF, Van de Werf F, Verheugt F, Wallentin L. 2012. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 33: 2569-2619.

Hamon M, Rao SV, Steg G, Valgimigli M, Verheugt F, Marso S, Gershlick A, Wang Y, Deliargyris E. 2012. Bivalirudin versus unfractionated heparin in percutaneous coronary intervention of patients having received initial fondaparinux treatment: a propensity matched study. EuroIntervention. 8: 486-492.

Sianos G, Werner GS, Galassi AR, Papafaklis MI, Escaned J, Hildick-Smith D, Christiansen EH, Gershlick A, Carlino M, Karlas A, Konstantinidis NV, Tomasello SD, Di Mario C, Reifart N. 2012. Recanalisation of Chronic Total coronary Occlusions: 2012 consensus document from the EuroCTO club. EuroIntervention. 8: 139-145.

Van de Werf F, Ardissino D, Bueno H, Collet JP, Gershlick A, Kolh P, Kristensen SD, Silber S, Verheugt F, Wojakowski W. 2012. Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines. Expert Rev Cardiovasc Ther. 10: 489-503.

Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM; INFUSE-AMI Investigators. Inc Gershlick AH. 2012.  Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 307: 1817-1826.

Kelly DJ, Gershlick T, Witzenbichler B, Guagliumi G, Fahy M, Dangas G, Mehran R, Stone GW. 2011. Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Am Heart J. 162(4): 663-70.

Maznyczka A, Myat A, Gershlick A. 2011. Discontinuation of metformin in the setting of coronary angiography: clinical uncertainty amongst physicians reflecting a poor evidence base. EuroIntervention. 7: 1103-1110.

Galassi AR, Tomasello SD, Reifart N, Werner GS, Sianos G, Bonnier H, Sievert H, Ehladad S, Bufe A, Shofer J, Gershlick A, Hildick-Smith D, Escaned J, Erglis A, Sheiban I, Thuesen L, Serra A, Christiansen E, Buettner A, Costanzo L, Barrano G, Di Mario C. 2011. In-hospital outcomes of percutaneous coronary intervention in patients with chronic total occlusion: insights from the ERCTO (European Registry of Chronic Total Occlusion) registry. EuroIntervention. 7: 472-479.

Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. 2011. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 4: 191-197.

Duckers HJ, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A, Bartunek J, Nienaber C, Macaya C, Peters N, Smits P, Siminiak T, van Mieghem W, Legrand V, Serruys PW. 2011. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention. 7: 805-12.

Armstrong PW, Gershlick A, Goldstein P, Wilcox R, Danays T, Bluhmki E, Van de Werf F; STREAM Steering Committee. 2010. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J. 160(1): 30-35.

Talwar V, Wurm P, Bankart MJ, Gershlick AH, DE Caestecker JS. 2010. Clinical trial: chest pain due to presumed gastro-oesophageal reflux in coronary artery disease - controlled study of lansoprazole versus placebo. Aliment Pharmacol Ther. 32: 191-9.

Remak E, Manson S, Hutton J, Brasseur P, Olivier E, Gershlick A. 2010. Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data. EuroIntervention. 5(7): 826-32.

Alahmar A, Redwood S, Gershlick A. 2009. Retrograde approach to chronic total occlusions: can septal vessels be used more than once? J Invasive Cardiol. 12: E234-6.

Camenzind E, Wijns W, Mauri L, Boersma E, Parikh K, Kurowski V, Gao R, Bode C, Greenwood JP, Gershlick A, O'Neill W, Serruys PW, Jorissen B, Steg PG; PROTECT Steering Committee and Investigators. 2009. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am Heart J. 158(6): 902-909.

Carver A, Rafelt S, Gershlick AH, Fairbrother KL, Hughes S, Wilcox R; REACT Investigators. 2009. Longer-term follow-up of patients recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial. J Am Coll Cardiol. 54(2): 118-26.

APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F. 2009. Wallentin Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation.  119(22): 2877-85.

Gershlick AH. 2009. Managing myocardial infarction in the elderly: time to bury inappropriate concerns instead. Eur Heart J. 30(8): 887-9.

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Mooney M, Kroshus T, Zijlstra F, Boonstra PW, Vermeersch P, Van Cauwelaer. 2009. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 360(10): 961-72.

Gershlick AH, Fearn S. 2008. Health economics: drug-eluting stents--are they worth the money? EuroIntervention. Suppl C C75-9.

Werner GS, Di Mario C, Galassi AR, Gershlick A, Reimers B, Sianos G, Sievert H, Lefevre T, Reifart N; EuroCTO Club. 2008. Chronic total coronary occlusions and the occluded artery trial. A critical appraisal. EuroIntervention. 4(1) 23-7.

Rubboli A, Halperin JL, Juhani Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Fat Tse H, Verheugt FW, Lip GY. 2008. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 40(6): 428-36.

Gershlick AH. 2008. Contemporary percutaneous coronary intervention--30 years in the making. Clin Med. 8(2): 171-2.

Veitch AM, Baglin TP, Gershlick AH, Harnden SM, Tighe R, Cairns S; British Society of Gastroenterology; British Committee for Standards in Haematology; British Cardiovascular Intervention Society. 2008. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut. 57(9): 1322-9.

Gershlick AH. 2008. Ensuring appropriate use of antiplatelet agents in the treatment of acute coronary syndromes--have cardiovascular physicians been given enough grace in getting it right? Heart. 94(2): 135-7.

Alp NJ, Gershlick AH, Carver A, Stevens SE, Wilcox R. 2008. Rescue angioplasty for failed thrombolysis in older patients: Insights from the REACT trial. Int J Cardiol. 125(2): 254-7.

Gershlick A, Kandzari DE, Leon MB, Wijns W, Meredith IT, Fajadet J, Popma JJ, Fitzgerald PJ, Kuntz RE; ENDEAVOR Investigators. 2007. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol. 100(8B): 45M-55M.

Denton-Beaumont RN, Banning AS, Gershlick AH. 2007. Malabsorption causing failure of pharmacological therapy in the treatment of atrial fibrillation. Int J Cardiol. 128(3): e87-8.

Gershlick AH, de Belder M, Chambers J, Hackett D, Keal R, Kelion A, Neubauer S, Pennell DJ, Rothman M, Signy M, Wilde P. 2007. Role of non-invasive imaging in the management of coronary artery disease: an assessment of likely change over the next 10 years. A report from the British Cardiovascular Society Working Group. Heart. 93(4): 423-31.

Jeilan M, Richardson G, Gershlick A. 2007. Transvenous pacing causing tamponade in patients receiving glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention. J Invasive Cardiol. 19(2): E40-2.

Gershlick AH, Richardson G. 2006. Drug eluting stents. BMJ. 333(7581): 1233-4.

Collet JP, Montalescot G, Le May M, Borentain M, Gershlick A. 2006. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol. 48(7): 1326-35.

Chitkara K, Hogrefe K, Vasa-Nicotera M, Swanson N, Gershlick AH. 2006. Eptifibatide-eluting stent as an antiproliferative and antithrombotic agent: in vitro evaluation. J Invasive Cardiol. 18(9): 417-22.

Schampaert E, Moses JW, Schofer J, Schlüter M, Gershlick AH, Cohen EA, Palisaitis DA, Breithardt G, Donohoe DJ, Wang H, Popma JJ, Kuntz RE, Leon MB; SIRIUS, E- and C-SIRIUS Investigators. 2006. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol. 98(1): 36-41.

Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP; e-Cypher Investigators. 2006. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation. 113(11): 1434-41.

Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, de Belder A, Davis J, Pitt M, Banning A, Baumbach A, Shiu MF, Schofield P, Dawkins KD, Henderson RA, Oldroyd KG, Wilcox R; REACT Trial Investigators. 2005. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 353(26): 2758-68.

Gershlick AH. 2005. Is there any place for oral anti-restenotic treatment in the era of drug eluting stents? Heart. 91(11): 1377-9.

Azeem T, Adlam D, Gershlick A. 2005. Evolution of vascular brachytherapy over time: data from the RENO-registry analysis. Int J Cardiol. 100(2): 225-8.

Dawkins KD, Gershlick T, de Belder M, Chauhan A, Venn G, Schofield P, Smith D, Watkins J, Gray HH; Joint Working Group on Percutaneous Coronary Intervention of the British Cardiovascular Intervention Society and the British Cardiac Society. 2005. Percutaneous coronary intervention: recommendations for good practice and training. Heart. 91(Suppl 6): vi1-27.

Ng E, Jilaihawi H, Gershlick AH. 2005. Symptomatic myocardial bridging--a niche indication for drug-eluting stents? Int J Cardiol. 99(3): 463-4.

Schlüter M, Schofer J, Gershlick AH, Schampaert E, Wijns W, Breithardt G; E- and C-SIRIUS Investigators. 2005. Direct stenting of native de novo coronary artery lesions with the sirolimus-eluting stent: a post hoc subanalysis of the pooled E- and C-SIRIUS trials. J Am Coll Cardiol. 45(1): 10-3.

Research

  • Ischemic Heart Disease
  • Coronary intervention
  • Novel intracoronary stents
  • Clinical trials
  • Novel Antiplatelet agents
  • Stent thrombosis and restenosis

Share this page: